This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2025 Jul 31;146(5):519-520.

doi: 10.1182/blood.2025029157.

Time-tested safety: FCARH143's 5-year myeloma journey

Samer Al Hadidi¹

Affiliations

PMID: 40742722
DOI: 10.1182/blood.2025029157

Editorial

Time-tested safety: FCARH143's 5-year myeloma journey

Samer Al Hadidi. Blood. 2025.

. 2025 Jul 31;146(5):519-520.

doi: 10.1182/blood.2025029157.

Author

Samer Al Hadidi¹

Affiliation

¹ University of Arkansas for Medical Sciences.

PMID: 40742722
DOI: 10.1182/blood.2025029157

No abstract available

PubMed Disclaimer

Comment on

A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up.
Tuazon SA, Portuguese AJ, Pont MJ, Cowan AJ, Cole GO, Sather BD, Song X, Thomas S, Wood BL, Blake M, Works MG, Shadman M, Liang EC, Wu QV, Voutsinas JM, Gooley TA, Turtle CJ, Till BG, Coffey DG, Maloney DG, Riddell SR, Green DJ. Tuazon SA, et al. Blood. 2025 Jul 31;146(5):535-545. doi: 10.1182/blood.2024027681. Blood. 2025. PMID: 40198877 Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems